The First Case of 99mTc-FAPI Uptake in Optic Nerve Sheath Meningioma-Reference-Cited by-同舟云学术

The First Case of 99mTc-FAPI Uptake in Optic Nerve Sheath Meningioma

Published:2024-09 Issue:9 Volume:49 Page:e453-e454
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Sahafi Pegah¹,Jafari Zarrin Ghabaei Farid¹,Aryana Kamran¹,Aledavood Seyed amir²,Aghaee Atena¹

Affiliation:

1. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Abstract This case study presents the first demonstration of FAPI ligand uptake in a patient with optic nerve sheath meningioma. The patient, a 23-year-old woman who had previously undergone surgery for refractory optic meningioma, was referred to our department for 177Lu-DOTATATE therapy. After 3 cycles of 177Lu-DOTATATE administration, her proptosis significantly decreased. Two months after her last therapeutic cycle, a 99mTc-FAPI scan was performed. The scan revealed a mass with moderately increased uptake in the left retro-orbital region. This study is believed to be the first to demonstrate FAPI ligand uptake in a patient with optic nerve sheath meningioma.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference10 articles.

1. Optic nerve sheath meningioma: current diagnosis and treatment;Neurosurg Focus,2007

2. Diagnosis and treatment of orbital optic nerve sheath meningioma;Cancer Control,2004

3. New concepts in the diagnosis and management of optic nerve sheath meningioma;J Neuroophthalmol,2006

4. The use of 68Ga-DOTATATE PET/CT in the non-invasive diagnosis of optic nerve sheath meningioma: a case report;Front Oncol,2018

5. Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients;J Nucl Med,2022